Please provide your email address to receive an email when new articles are posted on . A variety of options/tools are needed when treating patients with severe emphysema and breathlessness. A phase 3 ...

In Tarrant County, patients with severe chronic obstructive pulmonary disease, COPD, now have access to a procedure that can lessen airflow blockage and improve their quality of life. KERA’s Sam Baker ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The 2024 GOLD report newly highlights hyperinflation, ...

One patient could only walk 15 to 20 steps before needing to get back on her oxygen, making it difficult to find motivation to engage in daily activities. Another patient struggled with severe ...

Credit: Getty Images. The 2024 GOLD COPD Report includes updated research and recommendations that reflect shifts in thinking on COPD management. Vogelmeier, who heads the Department of Medicine, ...

More than 11 million people in the United States are living with chronic obstructive pulmonary disease (COPD), including more than 3 million people with emphysema, a type of COPD. This chronic lung ...

If you or a loved one suffers from severe COPD (Chronic Obstructive Pulmonary Disease) or advanced emphysema, you know just how difficult it can be to breathe. Every step can be a struggle. Now, there ...

Severe emphysema is common, is associated with severe symptoms and disability, entails much utilization of healthcare, and lacks disease-modifying treatments. Since the 1960s, various palliative ...

DEAR MAYO CLINIC: What is hyperinflation? What can cause it, what are its effects, and what can be done to reverse it? Can long-term hyperinflation lead to any other lung disorders or cause other ...

NEW YORK (Reuters Health) - Treatment with a stent coated with the drug paclitaxel to reduce hyperinflation of the lungs appears to be a feasible treatment for patients with severe emphysema, ...

REDWOOD CITY, Calif. & TOKYO--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the ...

Gerard Criner, MD, FACP, FACCP, professor and founding chair, Thoracic Medicine and Surgery, at the Lewis Katz School of Medicine at Temple University, discusses a new trial that investigated how long ...